UK Breast Cancer Radiotherapy Trial Passes 1,000 Participants as Five-Day Course Is Tested

More than 1,000 people have enrolled in a UK clinical trial examining whether breast cancer radiotherapy that includes an additional targeted dose can be delivered safely in five days rather than over several weeks, the British government and the study's research institute said on Friday, October 30.

The FAST-Forward Boost trial is operating at 39 hospitals and cancer centres across the United Kingdom. It is led by the Institute of Cancer Research in London and funded through the National Institute for Health and Care Research. Researchers are evaluating a shortened course that includes a tumour-site 'boost' dose, intended to reduce the risk of cancer returning.

The new milestone is an enrolment figure, not evidence that the experimental treatment schedule has already been shown to be equally safe or effective. Participants will be followed over time so investigators can compare outcomes, including whether the disease returns and whether patients experience side effects. The trial aims to recruit 4,830 people by 2028, with results expected in 2033, according to the Department of Health and Social Care.

If the shortened schedule proves suitable, some patients could avoid as many as 10 hospital visits. That could reduce travel burdens, time away from work and family, and pressure on radiotherapy services. Those potential benefits depend on the study's eventual findings and should not be interpreted as a change in current treatment guidance.

The trial builds on earlier research into shorter radiotherapy schedules for breast cancer, but specifically investigates delivering an additional targeted boost within the condensed course. That distinction matters because the safety and effectiveness of the combined approach are the questions the ongoing trial is designed to answer.

The government announced the milestone alongside other breast cancer initiatives, including the appointment of Member of Parliament Ashley Dalton as an adviser on delivery of the National Cancer Plan. Officials also reported that uptake among women receiving their first breast-screening invitation reached 63.6%, while roughly four in ten did not attend. Those screening statistics concern a separate part of cancer care and are not trial outcomes.

For now, the significance of the announcement lies in the scale of recruitment and the number of hospitals participating. Researchers have not announced final clinical results for FAST-Forward Boost, and decisions about an individual's radiotherapy schedule remain matters for their clinical team.